SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease.
At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology.
Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, a key driver of disease progression.
Ph2a Clinical Trial commencing in 2025.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 63 University Road, Belfast,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.signacor.co.uk
- Keywords
- SciLeads.
- HQ
- Belfast
Signacor Questions
Signacor's website is http://www.signacor.co.uk
Signacor's LinkedIn profile is https://uk.linkedin.com/company/signacorltd
Signacor has
3 employees.
View email and phone details for 3
employees at Signacor.
Signacor's industry is
Biotechnology Research
Signacor's top competitors are
Digital Science,
Klastherapeutics,
Scileads,
Anonox Gmbh,
Kinopharma,
Theraduty,
Invest Northern Ireland – Americas,
Ailsebio,
Apt Therapeutics,
Health Data Research Uk (Hdr Uk).
Signacor's categories are Biotechnology Research
Signacor's founding year is 2024
